KRT18P19: A Potential Drug Target and Biomarker (G339781)

Target Name: KRT18P19

NCBI ID: G339781

KRT18P19

Other Name(s): keratin 18 pseudogene 19 | Keratin 18 pseudogene 19

KRT18P19: A Potential Drug Target and Biomarker

Keratin 18 (K18) pseudogene 19 (KRT18P19) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its functions continue to be a subject of debate in the scientific community.

KRT18P19 is a small non-coding RNA molecule that is expressed in various tissues and cells, including hair, skin, and nervous system cells. It is a part of the known K18 gene family, which is responsible for the production of proteins involved in the development and maintenance of hair and nails. The K18 gene has four exons, and the pseudogene 19 gene is located between the second and third exons.

KRT18P19 has been shown to play a role in various biological processes, including cell growth, differentiation, and wound healing. Its expression has been associated with the growth and development of various tissues, including hair and nails, and its levels have been shown to increase in response to growth factors and mechanical stress.

One of the most significant aspects of KRT18P19 is its potential as a drug target. Its unique structure and expression pattern make it an attractive target for small molecules, which can interact with its various chemical components. Researchers have identified several potential drug candidates that have been shown to interact with KRT18P19 and are currently in the testing phase. These drugs have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, KRT18P19 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that KRT18P19 may be a useful biomarker for these diseases and could potentially serve as a diagnostic tool.

The role of KRT18P19 in cancer is a topic of particular interest. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have shown that KRT18P19 has been involved in the development of resistance to chemotherapy in cancer cells. This suggests that targeting KRT18P19 may be an effective way to treat cancer.

In neurodegenerative diseases, KRT18P19 has been shown to be involved in the development and progression of these diseases. Its expression has been associated with the loss of hair and nails in various neurodegenerative diseases, and its levels have been shown to increase in response to these conditions. This suggests that targeting KRT18P19 may be a potential way to treat these diseases.

In autoimmune disorders, KRT18P19 has been shown to be involved in the development and progression of these conditions. Its expression has been associated with the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. This suggests that targeting KRT18P19 may be a potential way to treat these disorders.

While the potential uses of KRT18P19 as a drug target and biomarker are still being explored, its unique structure and expression pattern make it an attractive target for research. Further studies are needed to fully understand its functions and potential as a drug target and biomarker.

Protein Name: Keratin 18 Pseudogene 19

The "KRT18P19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT18P19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets